Pros | 5Y returns in the top 25% of the category. 3Y returns in the top 25% of the category. Beats FD returns for both 3Y & 5Y duration. | Larger AUM within category. Beats FD returns for both 3Y & 5Y duration. | ||
Cons | - | - |
INDMoney rank | 2/8 | 6/8 | ||
Category,Subcateogry | Equity,Sector - Healthcare | Equity,Sector - Healthcare | ||
Fund Age | 12 Years | 12 Years | ||
Fund Size | 4131 Cr | 8459 Cr | ||
Min Investment | SIP ₹500 Lumpsum ₹5000 | SIP ₹100 Lumpsum ₹5000 | ||
Expense Ratio | 0.91% | 0.89% | ||
Exit Load | 0.5% | 1% | ||
Benchmark Index | BSE Healthcare TR INR | BSE Healthcare TR INR |
No of Holdings | 33 | 41 | ||
Top 5 Holdings | Sun Pharmaceuticals Industries Ltd (11.18%) Divi's Laboratories Ltd (7.26%) Max Healthcare Institute Ltd Ordinary Shares (5.62%) Cipla Ltd (4.41%) Lonza Group Ltd ADR (4.05%) | Sun Pharmaceuticals Industries Ltd (12.67%) Divi's Laboratories Ltd (8.07%) Lupin Ltd (7.26%) Cipla Ltd (6.29%) Apollo Hospitals Enterprise Ltd (5.97%) | ||
No of Sectors | 3 | 1 | ||
Top 3 Sectors | Health (93.34%) Basic Materials (6.66%) Government (1.79%) | Health (100%) | ||
Equity % | 96.07% | 99.66% | ||
Debt % | - | - | ||
P/E | - | - | ||
P/B | - | - | ||
Credit Quality | - | - | ||
Modified Duration | - | - | ||
YTM | - | - |
1-Month Return | -1.85% | -0.47% | ||
3-Month Return | -2.07% | -0.78% | ||
6-Month Return | 0.19% | 0.04% | ||
1-Year Return | -1.03% | -0.1% | ||
3-Year Return | 24.66% | 22.18% | ||
5-Year Return | 18.33% | 16.74% |
Sharpe | - | - | ||
Alpha | - | - | ||
Beta | - | - | ||
Standard Deviation | - | - | ||
Information Ratio | - | - |
Description | SBI Healthcare Opportunities Fund Direct Growth is an equity fund.The fund could potentially beat inflation in the long-run. | Nippon India Pharma Fund - Direct Plan - Growth Plan is an equity fund.The fund could potentially beat inflation in the long-run. | ||
Managers | Tanmaya Desai | Sailesh Raj Bhan,Lokesh Maru,Divya Sharma,Kinjal Desai |